ImageneBio Business Summary

ImageneBio, Inc. (IMA) is a clinical-stage biotechnology company that operates primarily through the development and future commercialization of targeted therapies for immunological, autoimmune, and inflammatory (I&I) diseases. Formed via the July 2025 merger of Inmagene Biopharmaceuticals and Ikena Oncology, the company generates revenue through strategic licensing agreements and R&D collaborations, typically structured around non-refundable upfront payments, development milestones, and tiered royalties. Its primary business segment is centered on its lead asset, IMG-007, a next-generation, non-depleting anti-OX40 monoclonal antibody currently in Phase 2b clinical trials for moderate-to-severe atopic dermatitis and alopecia areata. In a competitive landscape that includes Amarin (AMRN), Immuneering (IMRX), Rezolute (RZLT), and Larimar Therapeutics (LRMR), ImageneBio distinguishes itself by targeting the OX40 receptor rather than the ligand, aiming for a best-in-class profile characterized by extended half-life and superior safety through the preservation of T cells. The company is led by Chief Executive Officer Dr. Kristin Yarema, who previously served as CEO of Poseida Therapeutics (acquired by Roche) and held senior leadership roles at Atara Biotherapeutics and Amgen. The clinical organization is headed by Chief Medical Officer Dr. Ben Porter-Brown, an industry veteran with over 20 years of experience at MoonLake, Kymab, and Roche, while Dr. Kurinji Pandiyan serves as Chief Strategy and Operations Officer and Renuka Sivendran as Chief Technical Officer. ImageneBio was founded by Dr. Jonathan Jian Wang, a former Partner at OrbiMed and co-founder of OrbiMed Asia, who remains a key member of the Board of Directors. The company is backed by a high-pedigree investor syndicate including OrbiMed, Omega Funds, RTW Investments, Deep Track Capital, and Foresite Capital, with a board featuring notable figures such as David P. Bonita and Otello Stampacchia.